NUTRICIA'S Souvenaid, the nutrient drink specially designed to help Alzheimer's disease patients, has come under a cloud after some failed phase II clinical trial results published in Lancet Neurology.
While not totally dismissing the results as a fail, authors said bigger studies are needed to establish hoped-for efficacy.
According to the study, although patients in the Souvenaid group did have slightly less brain shrinkage on scans, which the researchers said was "promising", the treatment did not appear to offer an advantage based on various memory and cognitive tests.
Prof Tara Spires-Jones, a dementia expert at the University of Edinburgh, said a healthy lifestyle is still the most important factor in prevention - see thelancet.com.
The above article was sent to subscribers in Pharmacy Daily's issue from 08 Nov 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Nov 17
